Perioperative Techniques for the Use of Botulinum Toxin in Overactive Bladder: Results of a Multinational Online Survey of Urogynecologists in Germany, Austria, and Switzerland

Sören Lange, Marianne Koch, Rainer Lange, Heinrich Husslein, Wolfgang Umek, Barbara Bodner-Adler, Sören Lange, Marianne Koch, Rainer Lange, Heinrich Husslein, Wolfgang Umek, Barbara Bodner-Adler

Abstract

Introduction and hypothesis: Botulinum toxin (BoNT) is a widely used treatment for overactive bladder (OAB). Despite its common use, no standardized treatment regimen exists so far. The aim of this survey was to evaluate the variation in perioperative treatment strategies among members of the German-speaking urogynecologic societies.

Materials and methods: A clinical practice online survey was carried out between May 2021 and May 2022, and all members of the German, Swiss, and Austrian urogynecologic societies were invited to participate. Participants were grouped in two ways. First, they were grouped into (1) urogynecologists with board certification and (2) non-board-certified general obstetricians and gynecologists (OBGYNs). Second, we set a cut-off at 20 transurethral BoNT procedures per year to differentiate between (1) high- and (2) low-volume surgeons.

Results: One hundred and six completed questionnaires were received. Our results demonstrated that BoNT is mostly used as a third-line treatment (93%, n = 98/106), while high-volume surgeons used it significantly more often as a first/second-line treatment (21% vs. 6%, p = 0.029). Large variations existed in the use of perioperative antibiotics, preferred sites of injection, the number of injections, and the timing of the measurement of the postvoid residual volume (PVRV). Forty percent of participants did not offer outpatient treatment to patients. Local anesthesia (LA) was mostly used by board-certified urogynecologists (49% vs. 10%, p < 0.001) and high-volume surgeons (58% vs. 27%, p = 0.002). Injections into the trigone were also more often performed by board-certified urogynecologists and high-volume surgeons (22% vs. 3% (p = 0.023) and 35% vs. 6% (p < 0.001), respectively). PVRV was controlled between weeks 1 and 4 by only 54% of participants (n = 57/106). Clean intermittent self-catheterization (CISC) was infrequently taught (26%).

Conclusions: Our survey confirmed that BoNT is widely used by urogynecologists in the three German-speaking countries, but practice patterns vary widely, and no standardized method could be detected, despite interviewing urogynecologic experts. These results clearly demonstrate that there is a need for studies to define standardized treatment strategies for the best perioperative and surgical approach regarding the use of BoNT in patients with OAB.

Keywords: botulinum toxin; overactive bladder; survey.

Conflict of interest statement

R.L.: shareholder of coma-urogyn GmbH and conducts studies and speaks for Coloplast. Other authors declare no conflict of interest.

References

    1. Scioscia N.F., Edge P., Yanek L.R., Handa V.L. National Trends in Third-Line Treatment for Overactive Bladder Among Commercially Insured Women, 2010–2019. Urology. 2022:S0090429522009803. doi: 10.1016/j.urology.2022.11.006.
    1. Lin Y.-H., Chiang B.-J., Liao C.-H. Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders. Toxins. 2020;12:129. doi: 10.3390/toxins12020129.
    1. Palugan L., Cerea M., Cirilli M., Moutaharrik S., Maroni A., Zema L., Melocchi A., Uboldi M., Filippin I., Foppoli A., et al. Intravesical Drug Delivery Approaches for Improved Therapy of Urinary Bladder Diseases. Int. J. Pharm. X. 2021;3:100100. doi: 10.1016/j.ijpx.2021.100100.
    1. De Nunzio C., Brucker B., Bschleipfer T., Cornu J.-N., Drake M.J., Fusco F., Gravas S., Oelke M., Peyronnet B., Tutolo M., et al. Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men. Eur. Urol. 2021;79:492–504. doi: 10.1016/j.eururo.2020.12.032.
    1. Tyagi P., Kashyap M., Yoshimura N., Chancellor M., Chermansky C.J. Past, Present and Future of Chemodenervation with Botulinum Toxin in the Treatment of Overactive Bladder. J. Urol. 2017;197:982–990. doi: 10.1016/j.juro.2016.11.092.
    1. Drake M.J., Nitti V.W., Ginsberg D.A., Brucker B.M., Hepp Z., McCool R., Glanville J.M., Fleetwood K., James D., Chapple C.R. Comparative Assessment of the Efficacy of OnabotulinumtoxinA and Oral Therapies (Anticholinergics and Mirabegron) for Overactive Bladder: A Systematic Review and Network Meta-Analysis. BJU Int. 2017;120:611–622. doi: 10.1111/bju.13945.
    1. Amundsen C.L., Richter H.E., Menefee S.A., Komesu Y.M., Arya L.A., Gregory W.T., Myers D.L., Zyczynski H.M., Vasavada S., Nolen T.L., et al. OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial. JAMA. 2016;316:1366. doi: 10.1001/jama.2016.14617.
    1. Lightner D.J., Gomelsky A., Souter L., Vasavada S.P. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019. J. Urol. 2019;202:558–563. doi: 10.1097/JU.0000000000000309.
    1. Apostolidis A., Averbeck M.A., Sahai A., Rahnama’i M.S., Anding R., Robinson D., Gravas S., Dmochowski R. Can We Create a Valid Treatment Algorithm for Patients with Drug Resistant Overactive Bladder (OAB) Syndrome or Detrusor Overactivity (DO)? Results from a Think Tank (ICI-RS 2015) Neurourol. Urodyn. 2017;36:882–893. doi: 10.1002/nau.23170.
    1. Nambiar A.K., Arlandis S., Bø K., Cobussen-Boekhorst H., Costantini E., de Heide M., Farag F., Groen J., Karavitakis M., Lapitan M.C., et al. European Association of Urology Guidelines on the Diagnosis and Management of Female Non-Neurogenic Lower Urinary Tract Symptoms. Part 1: Diagnostics, Overactive Bladder, Stress Urinary Incontinence, and Mixed Urinary Incontinence. Eur. Urol. 2022;82:49–59. doi: 10.1016/j.eururo.2022.01.045.
    1. German Society for Gynecology and Obstetrics. Austrian Society for Gynecology and Obstetrics. Swiss Society of Gynaecology and Obstetrics Female Urinary Incontinence. Sk2-Level Guideline AWMF Regist. No 015-091 Dec 2021. [(accessed on 11 February 2023)]. Available online: .
    1. Shabir H., Hashemi S., Al-Rufayie M., Adelowo T., Riaz U., Ullah U., Alam B., Anwar M., de Preux L. Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome. Int. J. Environ. Res. Public. Health. 2021;18:8743. doi: 10.3390/ijerph18168743.
    1. Barba M., Lazar T., Cola A., Marino G., Manodoro S., Frigerio M. Learning Curve of Botulinum Toxin Bladder Injection for the Treatment of Refractory Overactive Bladder. Int. J. Womens Health. 2022;14:1–7. doi: 10.2147/IJWH.S345454.
    1. Mowat A., Maher C., Ballard E. Surgical Outcomes for Low-Volume vs High-Volume Surgeons in Gynecology Surgery: A Systematic Review and Meta-Analysis. Am. J. Obstet. Gynecol. 2016;215:21–33. doi: 10.1016/j.ajog.2016.02.048.
    1. Field M., Splevins A., Picaut P., van der Schans M., Langenberg J., Noort D., Foster K. AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients. Toxins. 2018;10:535. doi: 10.3390/toxins10120535.
    1. Albrecht P., Jansen A., Lee J.-I., Moll M., Ringelstein M., Rosenthal D., Bigalke H., Aktas O., Hartung H.-P., Hefter H. High Prevalence of Neutralizing Antibodies after Long-Term Botulinum Neurotoxin Therapy. Neurology. 2019;92:e48–e54. doi: 10.1212/WNL.0000000000006688.
    1. Bellows S., Jankovic J. Immunogenicity Associated with Botulinum Toxin Treatment. Toxins. 2019;11:491. doi: 10.3390/toxins11090491.
    1. Hendrickson W.K., Amundsen C.L., Rahn D.D., Meyer I., Bradley M.S., Smith A.L., Myers D.L., Jelovsek J.E., Lukacz E.S. Comparison of 100 U With 200 U of Intradetrusor OnabotulinumToxinA for Nonneurogenic Urgency Incontinence. Female Pelvic Med. Reconstr. Surg. 2021;27:140–146. doi: 10.1097/SPV.0000000000001020.
    1. Alsinnawi M., Torreggiani W., Sheikh M., Thomas A., Donnellan J., Flynn R., Mcdermott T.E.D., Thornhill J. Delayed Contrast-Enhanced MRI to Localize Botox after Cystoscopic Intravesical Injection. Int. Urol. Nephrol. 2015;47:893–898. doi: 10.1007/s11255-015-0976-2.
    1. Mehnert U., Boy S., Schmid M., Reitz A., von Hessling A., Hodler J., Schurch B. A Morphological Evaluation of Botulinum Neurotoxin A Injections into the Detrusor Muscle Using Magnetic Resonance Imaging. World J. Urol. 2009;27:397–403. doi: 10.1007/s00345-008-0362-0.
    1. Jo J.K., Kim K.N., Kim D.W., Kim Y.T., Kim J.Y., Kim J.Y. The Effect of OnabotulinumtoxinA According to Site of Injection in Patients with Overactive Bladder: A Systematic Review and Meta-Analysis. World J. Urol. 2018;36:305–317. doi: 10.1007/s00345-017-2121-6.
    1. El-Hefnawy A.S., Elbaset M.A., Taha D., Wadie B.S., Kenawy M., Shokeir A.A., Badry M.E. Trigonal-sparing versus Trigonal-involved Botox Injection for Treatment of Idiopathic Overactive Bladder: A Randomized Clinical Trial. LUTS Low. Urin. Tract Symptoms. 2021;13:22–30. doi: 10.1111/luts.12321.
    1. Abrar M., Pindoria N., Malde S., Chancellor M., DeRidder D., Sahai A. Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder: A Systematic Review. Eur. Urol. Focus. 2021;7:1448–1467. doi: 10.1016/j.euf.2020.06.013.
    1. Moore E.E., Jackson S.L., Boyko E.J., Scholes D., Fihn S.D. Urinary Incontinence and Urinary Tract Infection: Temporal Relationships in Postmenopausal Women. Obstet. Gynecol. 2008;111:317–323. doi: 10.1097/AOG.0b013e318160d64a.
    1. Houman J., Moradzadeh A., Patel D.N., Asanad K., Anger J.T., Eilber K.S. What Is the Ideal Antibiotic Prophylaxis for Intravesically Administered Botox Injection? A Comparison of Two Different Regimens. Int. Urogynecol. J. 2019;30:701–704. doi: 10.1007/s00192-018-3721-4.
    1. Bickhaus J.A., Vaughan M., Truong T., Li Y.-J., Siddiqui N.Y. A Comparison of Antibiotic Prophylaxis Regimens to Decrease the Risk of Post-Procedure Urinary Tract Infection after Onabotulinum Toxin A Injection. Int. Urogynecol. J. 2020;31:1907–1912. doi: 10.1007/s00192-020-04230-7.
    1. Bickhaus J.A., Bradley M.S., Amundsen C.L., Visco A.G., Truong T., Li Y.-J., Siddiqui N.Y. Does a Recent Urinary Tract Infection Increase the Risk of Postprocedure Urinary Tract Infection After Onabotulinum Toxin A? Female Pelvic Med. Reconstr. Surg. 2021;27:121–125. doi: 10.1097/SPV.0000000000000753.
    1. Mahajan S.T. Botulinum Toxin for Treatment of Overactive Bladder: Injection and Complications. [(accessed on 23 May 2022)]. Available online: .
    1. Nitti V.W., Dmochowski R., Herschorn S., Sand P., Thompson C., Nardo C., Yan X., Haag-Molkenteller C., Andreou C., Egerdie R.B., et al. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial. J. Urol. 2017;197 doi: 10.1016/j.juro.2016.10.109.
    1. Yokoyama O., Honda M., Yamanishi T., Sekiguchi Y., Fujii K., Nakayama T., Mogi T., Kitta T., Ohyama C., Kambe K., et al. OnabotulinumtoxinA (Botulinum Toxin Type A) for the Treatment of Japanese Patients with Overactive Bladder and Urinary Incontinence: Results of Single-dose Treatment from a Phase III, Randomized, Double-blind, Placebo-controlled Trial (Interim Analysis) Int. J. Urol. 2020;27:227–234. doi: 10.1111/iju.14176.
    1. Tay L.J., Harry D., Malde S., Sahai A. Cost Effectiveness of Sacral Neuromodulation and OnabotulinumtoxinA in Managing Refractory Idiopathic Overactive Bladder. Urology. 2021;149:1–10. doi: 10.1016/j.urology.2020.11.018.
    1. Hamid R., Lorenzo-Gomez M.-F., Schulte-Baukloh H., Boroujerdi A., Patel A., Farrelly E. OnabotulinumtoxinA Is a Well Tolerated and Effective Treatment for Refractory Overactive Bladder in Real-World Practice. Int. Urogynecol. J. 2021;32:65–74. doi: 10.1007/s00192-020-04423-0.
    1. Duthie J.B., Vincent M., Herbison G.P., Wilson D.I., Wilson D. Botulinum Toxin Injections for Adults with Overactive Bladder Syndrome. In: The Cochrane Collaboration, editor. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd.; Chichester, UK: 2011. p. CD005493.pub3.
    1. Miotla P., Cartwright R., Skorupska K., Bogusiewicz M., Markut-Miotla E., Futyma K., Rechberger T. Urinary Retention in Female OAB after Intravesical Botox Injection: Who Is Really at Risk? Int. Urogynecol. J. 2017;28:845–850. doi: 10.1007/s00192-016-3212-4.
    1. Ginsberg D.A., Boone T.B., Cameron A.P., Gousse A., Kaufman M.R., Keays E., Kennelly M.J., Lemack G.E., Rovner E.S., Souter L.H., et al. The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Treatment and Follow-Up. J. Urol. 2021;206:1106–1113. doi: 10.1097/JU.0000000000002239.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe